We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Insights

MYInsights provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

Data Compass conference reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy!

Engagements

MYBoard is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma

Source: Pharmacy Times articles The treatment becomes the first approved BCMAxCD3 bispecific antibody with the potential to achieve biweekly or monthly dosing in patients with relapsed/refractory multiple myeloma. Read More

Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma

Source: Myeloma : nature.com subject feeds Post Content Read More

Dual-Antigen Targeting in Myeloma: Improved Responses in Extramedullary Disease

Source: Pharmacy Times articles Shaji Kumar, MD, shares data and insights from the phase 2 RedirecTT-1 study. Read More
Latest Data

Latest Publications

Hepatitis B and C virus infection and risk of multiple myeloma: a systematic review and meta-analysis

BMC Cancer. 2025 Jun 4;25(1):998. doi: 10.1186/s12885-025-14420-5. ABSTRACT BACKGROUND: Multiple...

Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies

Blood Cancer J. 2025 May 26;15(1):104. doi: 10.1038/s41408-025-01312-x. ABSTRACT While observation...

Email

info@myeloma360.com